R-CHOP

ApprovedSmall molecule

IIncyte Biosciences Japan GK

R-CHOP is one of 233 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

232

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkins LymphomaActive, not recruiting

LymphomaActive, not recruiting

AnemiaActive, not recruiting

ImmunodeficiencyActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Untreated Follicular LymphomaRecruiting

DLBCL - Diffuse Large B Cell LymphomaNot yet recruiting

Follicular LymphomaActive, not recruiting

Non-Hodgkins LymphomaPhase 1/Phase 2

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

ImmunodeficiencyApproved

Active, not recruiting

Mantle Cell LymphomaPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

Untreated Follicular LymphomaPhase 3

Recruiting

DLBCL - Diffuse Large B Cell LymphomaPhase 2

Not yet recruiting

Follicular LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

R-CHOP

IIncyte Biosciences Japan GK

Approved

1 2

Oncaspar

SServier

Preclinical

15 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

PEG-Intron

Merck & Co.

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Non-Hodgkins Lymphoma

NCT04661007

Q4 2027

Phase 3Recruiting

Mantle Cell Lymphoma

NCT05051891

Q2 2028

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04546620

Q4 2029

Phase 2Not yet recruiting

Newly Diagnosed

NCT06890585

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma6 trials

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02660710·39 enrolled

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting·UUniversity Hospital Southampton NHS Foundation Trust·Phase 2·NCT04546620·453 enrolled

A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

Enrolling by invitation·SSecond Affiliated Hospital of Nanchang University·Phase 3·NCT07348575·80 enrolled

Show 3 more trials

Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

Unknown status·FFudan University·Phase 3·NCT03318835·162 enrolled

A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

Unknown status·NNanjing Yoko Biomedical Co., Ltd.·Phase 3·NCT03650933·360 enrolled

FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma

Completed·AAHS Cancer Control Alberta·N/A·NCT00530179·69 enrolled

Follicular Lymphoma2 trials

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Withdrawn·SSecuraBio·Phase 2·NCT02605694

Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00774826·534 enrolled

Newly Diagnosed2 trials

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Active, not recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT04231448·423 enrolled

Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

Not yet recruiting·LLi Zhiming·Phase 2·NCT06890585·128 enrolled

Mantle Cell Lymphoma2 trials

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT05051891·356 enrolled

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02633137·49 enrolled

PET/CT1 trial

Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL

Unknown status·FFudan University·Phase 2·NCT01804127·196 enrolled

9 more indications

Non-Hodgkins Lymphoma1 trial

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Active, not recruiting·IIncyte Biosciences Japan GK·Phase 1/2·NCT04661007·72 enrolled

Phase IB1 trial

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07398638·122 enrolled

Older Patients1 trial

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Completed·TThe Lymphoma Academic Research Organisation·Phase 3·NCT01865110·623 enrolled

Radiotherapy1 trial

R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL

Withdrawn·—·Phase 3·NCT02054559

Anemia1 trial

Erythropoietin for Management of Anemia Caused by Chemotherapy

Completed·KKosin University Gospel Hospital·Phase 2·NCT02890602·53 enrolled

Immunodeficiency1 trial

LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

Completed·PPETHEMA Foundation·Phase 4·NCT00466258·50 enrolled

Lymphoma1 trial

The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma

Unknown status·SShanghai Public Health Clinical Center··NCT03045471·50 enrolled

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study

Not yet recruiting·OOu Bai, MD/PHD·Phase 2·NCT07677813·66 enrolled

Untreated Follicular Lymphoma1 trial

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06549595·1,018 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for R-CHOP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-CHOP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-CHOP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte Biosciences Japan GK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IIncyte Biosciences Japan GK

R-CHOP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q4 2029

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma6 trials

Follicular Lymphoma2 trials

Newly Diagnosed2 trials

Mantle Cell Lymphoma2 trials

PET/CT1 trial

Non-Hodgkins Lymphoma1 trial

Phase IB1 trial

Older Patients1 trial

Radiotherapy1 trial

Anemia1 trial

Immunodeficiency1 trial

Lymphoma1 trial

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Untreated Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News